<p>Blood sampling was performed on day 7 and 15 of treatment -/+ exendin-4 with a low (20μg/kg/day) or high (200μg/kg/day) dose. Analysis of selected metabolic parameters was performed and the difference (∆) between day 7 and 15 was calculated for each mouse as indicated in methods for (a) GLP-1, (b) glucagon, (c) triglycerides and (d) total cholesterol. Results are expressed as mean ±SD. * p<0, 05, ** p<0, 01, *** p<0, 001 by one-way ANOVA followed by Bonferroni correction vs. saline treated control.</p
GLP-1 derivative NN2211 ameliorates glycemia and in-creases -cell mass in diabetic mice. Am J Physio...
Islet transplantation has become a viable clinical treatment, but is still compromised by long-term ...
OBJECTIVE: In addition to improve glucose intolerance, recent studies suggest that glucagon-like pep...
<p>Mice were transplanted with a minimal human islet graft (250 islets) and treated with or without ...
<p>Mice transplanted with a minimal human islet graft (250 islets) were treated with or without exen...
Exendin-4 reduces fasting and postprandial glucose and de-creases energy intake in healthy volunteer...
<p>Circulating levels of fasting blood glucose (a) and C-peptide (b) after 15 days of treatment -/+ ...
<p>(<b>A</b>) Body weights of saline-treated mice and mice treated with the GLP-1 receptor antagonis...
Background Exendin-4 is a similar peptide to GLP-1 and can interfere with various receptor...
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of...
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of...
Aims: Type 2 diabetes is highly prevalent in the elderly population. Glucagon like Peptide-1 mimetic...
<div><h3>Objective</h3><p>In addition to improve glucose intolerance, recent studies suggest that gl...
PEG modification is a common clinical strategy for prolonging the half-life of therapeutic proteins ...
Nonalcoholic fatty liver disease (NAFLD) is a serious form of chronic liver disease that is characte...
GLP-1 derivative NN2211 ameliorates glycemia and in-creases -cell mass in diabetic mice. Am J Physio...
Islet transplantation has become a viable clinical treatment, but is still compromised by long-term ...
OBJECTIVE: In addition to improve glucose intolerance, recent studies suggest that glucagon-like pep...
<p>Mice were transplanted with a minimal human islet graft (250 islets) and treated with or without ...
<p>Mice transplanted with a minimal human islet graft (250 islets) were treated with or without exen...
Exendin-4 reduces fasting and postprandial glucose and de-creases energy intake in healthy volunteer...
<p>Circulating levels of fasting blood glucose (a) and C-peptide (b) after 15 days of treatment -/+ ...
<p>(<b>A</b>) Body weights of saline-treated mice and mice treated with the GLP-1 receptor antagonis...
Background Exendin-4 is a similar peptide to GLP-1 and can interfere with various receptor...
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of...
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of...
Aims: Type 2 diabetes is highly prevalent in the elderly population. Glucagon like Peptide-1 mimetic...
<div><h3>Objective</h3><p>In addition to improve glucose intolerance, recent studies suggest that gl...
PEG modification is a common clinical strategy for prolonging the half-life of therapeutic proteins ...
Nonalcoholic fatty liver disease (NAFLD) is a serious form of chronic liver disease that is characte...
GLP-1 derivative NN2211 ameliorates glycemia and in-creases -cell mass in diabetic mice. Am J Physio...
Islet transplantation has become a viable clinical treatment, but is still compromised by long-term ...
OBJECTIVE: In addition to improve glucose intolerance, recent studies suggest that glucagon-like pep...